MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-29-2025
Agilent Technologies Operating Income 2011-2026 | A
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.35 B | 846 M | 941 M | 904 M | 807 M | 615 M | 522 M | 419 M | 386 M | 1.12 B | 1.07 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.35 B | 386 M | 816 M |
Quarterly Operating Income Agilent Technologies
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 360 M | 376 M | - | 333 M | 384 M | 383 M | 376 M | - | - | 360 M | 328 M | - | 336 M | 288 M | 215 M | 547 M | 230 M | 102 M | 250 M | 691 M | 225 M | 216 M | 229 M | 660 M | 221 M | 210 M | 206 M | 608 M | 201 M | 201 M | 155 M | 432 M | 146 M | 131 M | 115 M | 366 M | 144 M | 107 M | 124 M | 349 M | 131 M | 94 M | 217 M | 666 M | 236 M | 213 M | 271 M | 841 M | 270 M | 300 M | 211 M | 758 M | 281 M | 266 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 841 M | 94 M | 307 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 3.11 | -2.51 % | $ 101 K |  USA |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 22.32 | -3.71 % | $ 99.4 M |  Israel |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.45 | -3.67 % | $ 1.84 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 30.5 | -4.72 % | $ 328 M |  China |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 40.78 | 1.92 % | $ 1.13 B | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
DexCom
DXCM
|
598 M | $ 70.44 | 1.29 % | $ 27.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Guardant Health
GH
|
-444 M | $ 113.62 | 1.32 % | $ 13.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 147.36 | 4.03 % | $ 23.4 B | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 20.08 | 0.35 % | $ 1.08 B | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 234.95 | -0.44 % | $ 172 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 105.63 | -1.25 % | $ 4.17 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 12.48 | 0.28 % | $ 354 M | Israel |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 27.65 | -1.53 % | $ 836 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 102.21 | -0.22 % | $ 18.9 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.02 | 2.75 % | $ 4.57 B | USA |
 |
Medpace Holdings
MEDP
|
447 M | $ 602.32 | -1.41 % | $ 18.6 B | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 234.18 | -1.47 % | $ 42.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.28 | 0.27 % | $ 2.01 B | USA |
 |
National Research Corporation
NRC
|
40 M | $ 22.06 | -0.72 % | $ 541 M | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 219.04 | -0.3 % | $ 11.3 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.3 | 1.56 % | $ 902 M | USA |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 2.36 | 6.79 % | $ 599 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 188.87 | -0.33 % | $ 21 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 8.85 | 12.25 % | $ 1.15 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 272.02 | 0.42 % | $ 22.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 176.57 | -3.31 % | $ 14.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 688.67 | -3.73 % | $ 56.8 B | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 5.65 | -4.56 % | $ 512 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.67 | -2.3 % | $ 2.51 M | USA |